


1644 #3

Rev. 04/01

A015/CON2



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Examiner : Not Yet Assigned  
Group Art Unit : 1644  
Applicants : Susan L. Kalled et al.  
Serial No. : 10/015,832 Confirmation No.: 1236  
Filed : December 12, 2001  
For : METHOD OF THERAPEUTIC ADMINISTRATION OF  
ANTI-CD40L COMPOUNDS

New York, New York  
March 12, 2002

Hon. Commissioner for Patents  
P.O. Box 2327  
Arlington, Virginia 22202

TRANSMITTAL LETTER FOR  
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information Disclosure  
Statement in the above-identified application. This  
Statement is submitted:

- ☒ [X] within three months of the application filing date;
- ☐ [ ] more than three months from the application filing date but before the mailing date of the first Office Action on the merits.

In accordance with 37 C.F.R. § 1.97, submission of  
this Statement requires no fee. However, if for any reason  
a fee is due, the Director is hereby authorized to charge

payment of any fees required in connection with this  
Information Disclosure Statement to Deposit Account  
No. 06-1075. A duplicate copy of this letter is transmitted  
herewith.

Respectfully submitted,

*Shawn-Marie Mayrand*

Margaret A. Pierri (Reg. No. 30,709)  
Attorney for Applicants  
Shawn-Marie Mayrand (Reg. No. 48,986)  
Agent for Applicants  
c/o FISH & NEAVE  
1251 Avenue of the Americas  
New York, New York 10020-1104  
Tel.: (212) 596-9000

I Hereby Certify that this  
Correspondence is being  
Deposited with the U.S.  
Postal Service as First  
Class Mail in an Envelope  
Addressed to:  
COMMISSIONER FOR  
PATENTS P.O. Box 2327  
ARLINGTON, VA 22202 on

March 12, 2002  
Lillian Garcia

*Lillian Garcia*  
Signature of Person Signing



IDS/#3  
J 3/22/02

A015/CON2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned  
Group Art Unit : 1644  
Applicants : Susan L. Kalled et al.  
Serial No. : 10/015,832 Confirmation No.: 1235  
Filed : December 12, 2001  
For : METHOD OF THERAPEUTIC ADMINISTRATION OF  
ANTI-CD40L COMPOUNDS

New York, New York  
March 12, 2002

Hon. Commissioner for Patents  
P.O. Box 2327  
Arlington, Virginia 22202

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants  
make of record the following documents:\*

United States Patents

5,474,771	(Lederman et al.)	Issued December 12, 1995
5,540,926	(Aruffo et al.)	Issued June 30, 1996
5,674,492	(Armitage et al.)	Issued October 7, 1997
5,677,165	(de Boer et al.)	Issued October 14, 1997

---

\* For the Examiner's convenience, applicants have  
enclosed a completed Form PTO-1449, listing these documents.

5,683,693	(Noelle et al.)	Issued November 4, 1997
5,747,037	(Noelle et al.)	Issued May 5, 1998
5,833,987	(Noelle et al.)	Issued November 10, 1998
5,869,049	(Noelle et al.)	Issued February 9, 1999
5,876,718	(Noelle et al.)	Issued March 2, 1999
5,876,950	(Siadak et al.)	Issued March 2, 1999
5,902,585	(Noelle et al.)	Issued May 11, 1999
5,916,560	(Larsen et al.)	Issued June 29, 1999
5,942,229	(Noelle et al.)	Issued August 24, 1999
5,945,513	(Aruffo et al.)	Issued August 31, 1999
5,961,974	(Armitage et al.)	Issued October 5, 1999
5,962,406	(Armitage et al.)	Issued October 5, 1999
5,981,724	(Armitage et al.)	Issued November 9, 1999
5,993,816	(Lederman et al.)	Issued November 30, 1999
6,001,358	(Black et al.)	Issued December 14, 1999

#### PCT Patent Applications

PCT WO 93/08207, published April 29, 1993  
PCT WO 93/09812, published May 27, 1993  
PCT WO 94/04570, published March 3, 1994  
PCT WO 95/06480, published March 9, 1995  
PCT WO 95/06666, published March 9, 1995  
PCT WO 95/09653, published April 13, 1995  
PCT WO 96/23071, published August 1, 1996  
PCT WO 96/28568, published September 19, 1996  
PCT WO 96/40246, published December 19, 1996  
PCT WO 97/17446, published May 15, 1997  
PCT WO 98/30240, published July 16, 1998  
PCT WO 98/30241, published July 16, 1998

#### Articles

Alderson, M.R. et al. "CD40 Expression by Human Monocytes: Regulation by Cytokines and Activation of Monocytes by the Ligand for CD40", *J. Exp. Med.* 178:669-674 (1993)

Bajorath J. et al. "Identification of Residues on CD40 and its Ligand Which are Critical for the Receptor-Ligand Interaction", *Biochemistry* 34:1833-1844 (1995)

- Banchereau J. et al. "The CD40 Antigen and its Ligand", *Annual Rev. Immunol.* 12:881-922 (1994)
- Biancone, L. et al. "Inhibition of the CD40-CD40 Ligand Pathway Prevents Murine Membranous Glomerulonephritis", *Kidney Intl.* 48:458-468 (1995)
- Buhlmann, J.E. et al. "Therapeutic Potential for Blockade of the CD40 Ligand, gp39", *J. Clin. Immunol.* 16:83-89 (1996)
- Carbone, A. et al. "Expression of Functional CD40 Antigen on Reed-Sternberg Cells and Hodgkin's Disease Cell Lines", *Blood* 85:780-789 (1995)
- Clark, E.A. et al. "Activation of Human B Cells Mediated Through Two Distinct Cell Surface Differentiation Antigens, Bp35 and Bp50", *Proc. Natl. Acad. Sci. USA* 83:4494-4498 (1986).
- Cleary, A.M. et al. "Opposing Roles of CD95 (Fas/APO-1) and CD40 in the Death and Rescue of Human Low Density Tonsillar B Cells", *J. Immunol.* 155:3329-3337 (1995)
- Durie, F.H. et al. "The Role of CD40 and its Ligand (gp39) in Peripheral and Central Tolerance and its Contribution to Autoimmune Disease", *Res. Immunol.* 145:200-205 (1994)
- Durie, F.H. et al. "The Role of CD40 in the Regulation of Humoral and Cell-Mediated Immunity", *Immunol. Today* 15:406-411 (1994)
- Durie, F.H. et al. "Prevention of Collagen-Induced Arthritis with an Antibody to gp39, the Ligand for CD40", *Science* 261:1328-1330 (1993)
- Early, G.S. et al. "Anti-CD40 Ligand Antibody Treatment Prevents the Development of Lupus-like Nephritis in a Subset of New Zealand Black x New Zealand White Mice", *J. Immunol.* 157:3159-3164 (1996)
- Fanslow, W.C. et al. "Soluble Forms of CD40 Inhibit Biologic Responses of Human B Cells", *J. Immunol.* 149:655-660 (1992)
- Francisco, J.A. et al. "In vivo Efficacy and Toxicity of a Single-Chain Immunotoxin Targeted to CD40", *Blood* 89:4493-4500 (1997)

- Freudenthal, P.S. et al. "The Distinct Surface of Human Blood Dendritic Cells, as Observed After an Improved Isolation Method", *Proc. Natl. Acad. Sci. USA* 87:7698-7702 (1990)
- Galy, A.H.M. et al. "CD40 is Functionally Expressed on Human Thymic Epithelial Cells", *J. Immunol.* 149:775-782 (1992)
- Gerristse, K. et al. "CD40-CD40 Ligand Interactions in Experimental Allergic Encephalomyelitis and Multiple Sclerosis", *Proc. Nat. Acad. Sci. USA* 93:2499-2504 (1996)
- Gray, D. et al. "Memory B Cell Development but not Germinal Center Formation is Impaired by in vivo Blockade of CD40-CD40 Ligand Interaction", *J. Exp. Med.* 180:141-154 (1994)
- Hasbold, J. et al. "Properties of Mouse CD40: Cellular Distribution of CD40 and B Cell Activation by Monoclonal Anti-Mouse CD40 Antibodies", *Eur. J. Immunol.* 24:1835-1842 (1994)
- Hollenbaugh, D. et al. "Expression of Functional CD40 by Vascular Endothelial Cells", *J. Exp. Med.* 182:33-40 (1995)
- Kahan "Immunosuppressive Therapy", *Curr. Opin. Immunol.* 4:553-560 (1992)
- Karmann, K. et al. "CD40 on Human Endothelial Cells: Inducibility by Cytokines and Functional Regulation of Adhesion Molecule Expression", *Proc. Natl. Acad. Sci. USA* 92:4342-4346 (1995)
- Karpusas, M. et al. "2Å Crystal Structure of an Extracellular Fragment of Human CD40 Ligand", *Structure* 3:1031-1039 (1995)
- Kuntz, I.D. "Structure-Based Strategies for Drug Design and Discovery", *Science* 257:1078-1082 (1992)
- Kuwana, M. et al. "T and B Cell Collaboration is Essential for the Autoantibody Response to DNA Topoisomerase 1 in Systemic Sclerosis", *J. Immunol.* 155:2703-2714 (1995)
- Laman, J.D. et al. "The Role of GP39 (CD40 Ligand) in EAE and MS", *J. Neuroimmunol.* 54:175 (1994)
- Larsen, C.P. et al. "CD40-gp39 Interactions Play a Critical Role During Allograft Rejection", *Transplantation* 61:4-9 (1996)

Law, C-L. et al. "Analysis of Expression and Function of CD40 on Normal and Leukemic Human B Cell Precursors", *Leukemia* 4:732-738 (1990)

Lederman, S. et al. "The Understanding of Contact-Dependent T-Cell Helper Function in Molecular, Cellular and Physiological Detail", *Res. Immunol.* 145:215-222 (1994)

Mohan, C. et al. "Interaction Between CD40 and its Ligand gp39 in the Development of Murine Lupus Nephritis", *J. Immunol.* 154:1470-1480 (1995)

Merck Manual of Diagnosis and Therapy, 16th Ed. "Idiopathic Infiltrative Diseases of the Lungs", Merck Research Laboratories, Rahway, NJ, pp.718-720 (1992)

O'Grady, J.T. et al. "CD40 Expression in Hodgkin's Disease", *Am. J. Pathol.* 144:2126 (1994)

Paulie, S. et al. "A p50 Surface Antigen Restricted to Human Urinary Bladder Carcinomas and B Lymphocytes", *Cancer Immunol. Immunother.* 20:23-28 (1985)

Potocnik, A.J. et al. "Expression of Activation Antigens on T Cells in Rheumatoid Arthritis Patients", *Scand. J. Immunol.* 31:213-224 (1990)

Rao et al. "Reversal of Chronic Rejection in Mouse Aortic Allografts by Combined Treatment with CTLA-Ig and Anti-CD40L Monoclonal Antibody", *Human Immunol.* 55:15 (1997)

Stüber, E. et al. "Blocking the CD40L-CD40 Interaction in vivo Specifically Prevents the Priming of T Helper 1 Cells Through the Inhibition of Interleukin 12 Secretion", *J. Exp. Med.* 183: 693-698 (1996)

Uckun, F.M. et al. "Temporal Association of CD40 Antigen Expression with Discrete Stages of Human B-Cell Ontogeny and the Efficacy of Anti-CD40 Immunotoxins Against Clonogenic B-Lineage Acute Lymphoblastic Leukemia as well as B-Lineage Non-Hodgkin's Lymphoma Cells", *Blood* 76:2449-2456 (1990)

Urashima, M. et al. "CD40 Ligand Triggered Interleukin-6 Secretion in Multiple Myeloma", *Blood* 85:1903-1912 (1995)

Valent, P. et al. "Further Characterization of Surface Membrane Structures Expressed on Human Basophils and Mast Cells", *Int. Arch. Allergy Appl. Immunol.* 91:198-203 (1990)

Westendorf, J.J. et al. "Molecular and Biological Role of CD40 in Multiple Myeloma", *Curr. Top. Microbiol. Immunol.* 194:63-72 (1995)

Westendorf, J.J. et al. "CD40 Expressions in Malignant Plasma Cells", *J. Immunol.* 152:117-128 (1994)

Yellin, M.J. et al. "Human Fibroblasts and Endothelial Cells Express CD40 and are Activated by CD40L+ Cells," Poster session at 9th International Congress of Immunology meeting in San Francisco, California (Abstract available July 23, 1995)

Yellin, M.J. et al. "Ligation of CD40 on Fibroblasts Induces CD54 (ICAM-1) and CD106 (VCAM-1) Upregulation and IL-6 Production and Proliferation," *J. Leuk. Biol.* 58:209-216 (1995)

Yellin, M.J. et al. "Functional Interactions of T Cells with Endothelial Cells: The Role of CD40L-CD40 Mediated Signals," *J. Exp. Med.* 182:1857-1864 (1995)

Yellin M.J. et al. "In situ Characterization of CD40L and CD40 Expression in Glomerulonephritis (GN)", *ASBMB/ASIP/AAL Joint Meeting* (Abstract available May 1, 1996)

Yellin M.J. et al. "Function of CD40 Molecules Expressed on Cultured Synovial Membrane Fibroblasts", *FASEB J.* 9:A774 - Abstract No. 4483 (1995)

Young, L.S. et al. "Identification of a Human Epithelial Cell Surface Protein Sharing an Epitope with the C3d/Epstein-Barr Virus Receptor Molecule of B Lymphocytes," *Intl. J. Cancer* 43:786-794 (1989)



OTHER REFERENCES

Biogen Inc. Press Release, October 21, 1999, Biogen Says it Has Halted Several Trials of Anti-CD40 Ligand Monoclonal Antibody"

Biogen, Inc. Press Release, November 2, 1999, "Biogen Says It Has Stopped Ongoing Trials of Anti-CD40 Ligand Monoclonal Antibody"

Press Release from Biogen website ([www.prnewswire.com](http://www.prnewswire.com)), "Biogen Says it Has Halted Several Trials of Anti-CD40 Ligand Monoclonal Antibody", October 21, 1999

Press Release from Biogen website ([www.prnewswire.com](http://www.prnewswire.com)), "Biogen Says it Has Stopped Ongoing Trials of Anti-CD40 Ligand Monoclonal Antibody", November 2, 1999

Press Release from IDEC Pharmaceuticals, Inc. (April 20, 2000)

Press Release from IDEC Pharmaceuticals, Inc. (January 29, 2001)

Written Opinion dated October 12, 1998 in PCT/US98/23482 (WO 98/30240)

January 8, 1999 Reply to Written Opinion dated October 12, 1998 in PCT/US98/23482 (WO 98/30240)

Written Opinion dated October 12, 1998 in PCT/US98/00573 (WO 98/30241)

January 8, 1999 Reply to Written Opinion dated October 12, 1998 in PCT/US98/00573 (WO 98/30241)

Pursuant to 37 C.F.R. § 1.98(d), copies of these documents are not being submitted because the documents were previously cited by or submitted to the Patent Office in parent patent application Serial No. 09/346,653, filed July 1, 1999 (AO15/US).

Applicants respectfully request that the above-cited documents be (1) fully considered by the Examiner during the course of the examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO-1449, duly

initialed by the Examiner, be forwarded to the undersigned with the next official communication.

Applicants request favorable action in this application.

Respectfully submitted,

*Shawn Marie Mayrand*

Margaret A. Pierri (Reg. No. 30,709)  
Attorney for Applicants  
Shawn-Marie Mayrand (Reg. No. 48,986)  
Agent for Applicants  
c/o FISH & NEAVE  
1251 Avenue of the Americas  
New York, New York 10020-1104  
Tel.: (212) 596-9000  
Fax.: (212) 596-9090

I Hereby Certify that this  
Correspondence is being  
Deposited with the U.S.  
Postal Service as First  
Class Mail in an Envelope  
Addressed to:  
COMMISSIONER FOR  
PATENTS P.O. Box 2327  
ARLINGTON, VA 22202 on

March 12, 2002

Lillian Garcia

*Lillian Garcia*  
Signature of Person Signing

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
A015/CON2SERIAL NO.  
10/015,832INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Susan L. Kalled, et al.CONFIRMATION NO.  
1235FILING DATE  
December 12, 2001GROUP  
1644

## U.S. PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,474,771	12/12/95	Lederman et al.	424	85.8	Nov. 15, 1991
	5,540,926	6/30/96	Aruffo et al.	424	153.1	Sept. 2, 1992
	5,674,492	10/7/97	Armitage et al.	424	144.1	Dec. 23, 1993 Dec. 21, 1994
	5,677,165	10/14/97	de Boer et al.	435	240.27	July 9, 1992 May 28, 1993
	5,683,693	11/4/97	Noelle et al.	424	144.1	April 25, 1994
	5,747,037	5/5/98	Noelle et al.	424	154.1	Sept. 2, 1993 April 25, 1994 June 7, 1995
	5,833,987	11/10/98	Noelle et al.	424	154.1	June 7, 1995
	5,869,049	2/9/99	Noelle et al.	424	154.1	April 25, 1994
	5,876,718	3/2/99	Noelle et al.	424	154.1	March 27, 1998
	5,876,950	3/2/99	Siadak et al.	435	7.23	January 26, 1995
	5,902,585	5/11/99	Noelle et al.	424	144.1	August 5, 1997
	5,916,560	6/29/99	Larsen et al.	424	154.1	March 20, 1997
	5,942,229	8/24/99	Noelle et al.	424	154.1	June 7, 1995
	5,945,513	8/31/99	Aruffo et al.	530	387.3	July 30, 1996
	5,961,974	10/5/99	Armitage et al.	424	154.1	May 24, 1994
	5,962,406	10/5/99	Armitage et al.	514	8	June 7, 1995
	5,981,724	11/9/99	Armitage et al.	536	23.5	June 7, 1995
	5,993,816	11/30/99	Lederman et al.	424	154.1	June 7, 1995
	6,001,358	12/14/99	Black et al.	424	154.1	November 7, 1995

EXAMINER

DATE CONSIDERED


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
A015/CON2SERIAL NO.  
10/015,832INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Susan L. Kalled, et al.CONFIRMATION NO.  
1235FILING DATE  
December 12, 2001GROUP  
1644

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 93/08207	4/29/93	PCT	C07H	21/00		
	WO 93/09812	5/27/93	PCT	A61K	39/395		
	WO 94/04570	3/3/94	PCT	C07K	15/06		
	WO 95/06480	3/9/95	PCT	A61K	39/395		
	WO 95/06666	3/9/95	PCT	C07K	16/28		
	WO 95/09653	4/13/95	PCT	A61K	39/395		
	WO 96/23071	8/1/96	PCT	C12N	15/13		
	WO 96/28568	9/19/96	PCT	C12P	21/02		
	WO 96/40246	12/19/96	PCT	A61K	39/395		
	WO 97/17446	5/15/97	PCT	C12N	15/13		
	WO 98/30240	7/16/98	PCT	A61K	39/395		
	WO 98/30241	7/16/98	PCT	A61K	39/395		



## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Alderson, M.R. et al. "CD40 Expression by Human Monocytes: Regulation by Cytokines and Activation of Monocytes by the Ligand for CD40", <i>J. Exp. Med.</i> 178:669-674 (1993)
	Bajorath J. et al. "Identification of Residues on CD40 and its Ligand Which are Critical for the Receptor-Ligand Interaction", <i>Biochemistry</i> 34:1833-1844 (1995)
	Banchereau J. et al. "The CD40 Antigen and its Ligand", <i>Annual Rev. Immunol.</i> 12:881-922 (1994)
	Biancone, L. et al. "Inhibition of the CD40-CD40 Ligand Pathway Prevents Murine Membranous Glomerulonephritis", <i>Kidney Intl.</i> 48:458-468 (1995)
	Buhlmann, J.E. et al. "Therapeutic Potential for Blockade of the CD40 Ligand, gp39", <i>J. Clin. Immunol.</i> 16:83-89 (1996)
	Carbone, A. et al. "Expression of Functional CD40 Antigen on Reed-Sternberg Cells and Hodgkin's Disease Cell Lines", <i>Blood</i> 85:780-789 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
A015/CON2SERIAL NO.  
10/015,832INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Susan L. Kalled, et al.CONFIRMATION NO.  
1235FILING DATE  
December 12, 2001GROUP  
1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER  
INITIAL

- Clark, E.A. et al. "Activation of Human B Cells Mediated Through Two Distinct Cell Surface Differentiation Antigens, Bp35 and Bp50", *Proc. Natl. Acad. Sci. USA* 83:4494-4498 (1986)
- Cleary, A. M. et al. "Opposing Roles of CD95 (Fas/APO-1) and CD40 in the Death and Rescue of Human Low Density Tonsillar B Cells", *J. Immunol.* 155:3329-3337 (1995)
- Durie, F.H. et al. "The Role of CD40 and its Ligand (gp39) in Peripheral and Central Tolerance and its Contribution to Autoimmune Disease", *Res. Immunol.* 145:200-205 (1994)
- Durie, F.H. et al. "The Role of CD40 in the Regulation of Humoral and Cell-Mediated Immunity", *Immunol. Today* 15:406-411 (1994)
- Durie, F.H. et al. "Prevention of Collagen-Induced Arthritis with an Antibody to gp39, the Ligand for CD40", *Science* 261:1328-1330 (1993)
- Early, G.S. et al. "Anti-CD40 Ligand Antibody Treatment Prevents the Development of Lupus-like Nephritis in a Subset of New Zealand Black x New Zealand White Mice", *J. Immunol.* 157:3159-3164 (1996)
- Fanslow W. C. et al. "Soluble Forms of CD40 Inhibit Biologic Responses of Human B Cells", *J. Immunol.* 149:655-660 (1992)
- Francisco, J.A. et al. "In vivo Efficacy and Toxicity of a Single-Chain Immunotoxin Targeted to CD40", *Blood* 89: 4493-4500 (1997)
- Freudenthal, P.S. et al. "The Distinct Surface of Human Blood Dendritic Cells, as Observed After an Improved Isolation Method", *Proc. Natl. Acad. Sci. USA* 87:7698-7702 (1990)
- Galy, A.H.M. et al. "CD40 is Functionally Expressed on Human Thymic Epithelial Cells", *J. Immunol.* 149:775-782 (1992)
- Gerritse, K. et al., "CD40-CD40 Ligand Interactions in Experimental Allergic Encephalomyelitis and Multiple Sclerosis", *Proc. Nat. Acad. Sci. USA* 93:2499-2504 (1996)
- Gray, D. et al. "Memory B Cell Development but not Germinal Center Formation is Impaired by in vivo Blockade of CD40-CD40 Ligand Interaction", *J. Exp. Med.* 180:141-154 (1994)
- Hasbold, J. et al. "Properties of Mouse CD40: Cellular Distribution of CD40 and B Cell Activation by Monoclonal Anti-Mouse CD40 Antibodies", *Eur. J. Immunol.* 24:1835-1842 (1994)
- Hollenbaugh, D. et al. "Expression of Functional CD40 by Vascular Endothelial Cells", *J. Exp. Med.* 182:33-40 (1995)
- Kahan, "Immunosuppressive Therapy", *Curr. Opin. Immunol.* 4:553-560 (1992)
- Karmann, K. et al. "CD40 on Human Endothelial Cells: Inducibility by Cytokines and Functional Regulation of Adhesion Molecule Expression", *Proc. Natl. Acad. Sci. USA* 92:4342-4346 (1995)
- Karpusas, M. et al. "2Å Crystal Structure of an Extracellular Fragment of Human CD40 Ligand", *Structure* 3:1031-1039 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
A015/CON2SERIAL NO.  
10/015,832INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Susan L. Kalled, et al.CONFIRMATION NO.  
1235FILING DATE  
December 12, 2001GROSS  
1644

## U.S. PATENT DOCUMENTS



EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,474,771	12/12/95	Lederman et al.	424	85.8	Nov. 16, 1991
	5,540,926	6/30/96	Aruffo et al.	424	153.1	Sept. 4, 1992
	5,674,492	10/7/97	Armitage et al.	424	144.1	Dec. 23, 1993 Dec. 21, 1994
	5,677,165	10/14/97	de Boer et al.	435	240.27	July 9, 1992 May 28, 1993
	5,683,693	11/4/97	Noelle et al.	424	144.1	April 25, 1994
	5,747,037	5/5/98	Noelle et al.	424	154.1	Sept. 2, 1993 April 25, 1994 June 7, 1995
	5,833,987	11/10/98	Noelle et al.	424	154.1	June 7, 1995
	5,869,049	2/9/99	Noelle et al.	424	154.1	April 25, 1994
	5,876,718	3/2/99	Noelle et al.	424	154.1	March 27, 1998
	5,876,950	3/2/99	Siadak et al.	435	7.23	January 26, 1995
	5,902,585	5/11/99	Noelle et al.	424	144.1	August 5, 1997
	5,916,560	6/29/99	Larsen et al.	424	154.1	March 20, 1997
	5,942,229	8/24/99	Noelle et al.	424	154.1	June 7, 1995
	5,945,513	8/31/99	Aruffo et al.	530	387.3	July 30, 1996
	5,961,974	10/5/99	Armitage et al.	424	154.1	May 24, 1994
	5,962,406	10/5/99	Armitage et al.	514	8	June 7, 1995
	5,981,724	11/9/99	Armitage et al.	536	23.5	June 7, 1995
	5,993,816	11/30/99	Lederman et al.	424	154.1	June 7, 1995
	6,001,358	12/14/99	Black et al.	424	154.1	November 7, 1995

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
A015/CON2SERIAL NO.  
10/015,832INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Susan L. Kalled, et al.CONFIRMATION NO.  
1235FILING DATE  
December 12, 2001GROUP  
1644

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	
	WO 93/08207	4/29/93	PCT	C07H	21/00		
	WO 93/09812	5/27/93	PCT	A61K	39/395		
	WO 94/04570	3/3/94	PCT	C07K	15/06		
	WO 95/06480	3/9/95	PCT	A61K	39/395		
	WO 95/06666	3/9/95	PCT	C07K	16/28		
	WO 95/09653	4/13/95	PCT	A61K	39/395		
	WO 96/23071	8/1/96	PCT	C12N	15/13		
	WO 96/28568	9/19/96	PCT	C12P	21/02		
	WO 96/40246	12/19/96	PCT	A61K	39/395		
	WO 97/17446	5/15/97	PCT	C12N	15/13		
	WO 98/30240	7/16/98	PCT	A61K	39/395		
	WO 98/30241	7/16/98	PCT	A61K	39/395		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Alderson, M.R. et al. "CD40 Expression by Human Monocytes: Regulation by Cytokines and Activation of Monocytes by the Ligand for CD40", <i>J. Exp. Med.</i> 178:669-674 (1993)
	Bajorath J. et al. "Identification of Residues on CD40 and its Ligand Which are Critical for the Receptor-Ligand Interaction", <i>Biochemistry</i> 34:1833-1844 (1995)
	Banchereau J. et al. "The CD40 Antigen and its Ligand", <i>Annual Rev. Immunol.</i> 12:881-922 (1994)
	Biancone, L. et al. "Inhibition of the CD40-CD40 Ligand Pathway Prevents Murine Membranous Glomerulonephritis", <i>Kidney Intl.</i> 48:458-468 (1995)
	Buhlmann, J.E. et al. "Therapeutic Potential for Blockade of the CD40 Ligand, gp39", <i>J. Clin. Immunol.</i> 16:83-89 (1996)
	Carbone, A. et al. "Expression of Functional CD40 Antigen on Reed-Sternberg Cells and Hodgkin's Disease Cell Lines", <i>Blood</i> 85:780-789 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
A015/CON2SERIAL NO.  
10/015,832

MAR 15 2002

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Susan L. Kalled, et al.CONFIRMATION NO.  
1235FILING DATE  
December 12, 2001GROUP  
1644

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER  
INITIALClark, E.A. et al. "Activation of Human B Cells Mediated Through Two Distinct Cell Surface Differentiation Antigens, Bp35 and Bp50", *Proc. Natl. Acad. Sci. USA* 83:4494-4498 (1986)Cleary, A. M. et al. "Opposing Roles of CD95 (Fas/APO-1) and CD40 in the Death and Rescue of Human Low Density Tonsillar B Cells", *J. Immunol.* 155:3329-3337 (1995)Durie, F.H. et al. "The Role of CD40 and its Ligand (gp39) in Peripheral and Central Tolerance and its Contribution to Autoimmune Disease", *Res. Immunol.* 145:200-205 (1994)Durie, F.H. et al. "The Role of CD40 in the Regulation of Humoral and Cell-Mediated Immunity", *Immunol. Today* 15:406-411 (1994)Durie, F.H. et al. "Prevention of Collagen-Induced Arthritis with an Antibody to gp39, the Ligand for CD40", *Science* 261:1328-1330 (1993)Early, G.S. et al. "Anti-CD40 Ligand Antibody Treatment Prevents the Development of Lupus-like Nephritis in a Subset of New Zealand Black x New Zealand White Mice", *J. Immunol.* 157:3159-3164 (1996)Fanslow W. C. et al. "Soluble Forms of CD40 Inhibit Biologic Responses of Human B Cells", *J. Immunol.* 149:655-660 (1992)Francisco, J.A. et al. "In vivo Efficacy and Toxicity of a Single-Chain Immunotoxin Targeted to CD40", *Blood* 89: 4493-4500 (1997)Freudenthal, P.S. et al. "The Distinct Surface of Human Blood Dendritic Cells, as Observed After an Improved Isolation Method", *Proc. Natl. Acad. Sci. USA* 87:7698-7702 (1990)Galy, A.H.M. et al. "CD40 is Functionally Expressed on Human Thymic Epithelial Cells", *J. Immunol.* 149:775-782 (1992)Gerritse, K. et al., "CD40-CD40 Ligand Interactions in Experimental Allergic Encephalomyelitis and Multiple Sclerosis", *Proc. Nat. Acad. Sci. USA* 93:2499-2504 (1996)Gray, D. et al. "Memory B Cell Development but not Germinal Center Formation is Impaired by in vivo Blockade of CD40-CD40 Ligand Interaction", *J. Exp. Med.* 180:141-154 (1994)Hasbold, J. et al. "Properties of Mouse CD40: Cellular Distribution of CD40 and B Cell Activation by Monoclonal Anti-Mouse CD40 Antibodies", *Eur. J. Immunol.* 24:1835-1842 (1994)Hollenbaugh, D. et al. "Expression of Functional CD40 by Vascular Endothelial Cells", *J. Exp. Med.* 182:33-40 (1995)Kahan, "Immunosuppressive Therapy", *Curr. Opin. Immunol.* 4:553-560 (1992)Karmann, K. et al. "CD40 on Human Endothelial Cells: Inducibility by Cytokines and Functional Regulation of Adhesion Molecule Expression", *Proc. Natl. Acad. Sci. USA* 92:4342-4346 (1995)Karpusas, M. et al. "2Å Crystal Structure of an Extracellular Fragment of Human CD40 Ligand", *Structure* 3:1031-1039 (1995)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
A015/CON2SERIAL NO.  
10/015,832INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Susan L. Kalled, et al.CONFIRMATION NO.  
1235FILING DATE  
December 12, 2001GROUP  
1644

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Kuntz, I.D. "Structure-Based Strategies for Drug Design and Discovery", <i>Science</i> 257:1078-1082 (1992)
	Kuwana, M. et al. "T and B Cell Collaboration is Essential for the Autoantibody Response to DNA Topoisomerase 1 in Systemic Sclerosis", <i>J. Immunol.</i> 155:2703-2714 (1995)
	Laman, J.D. et al. "The Role of GP39 (CD40 Ligand) in EAE and MS", <i>J. Neuroimmunol.</i> 54:175 (1994)
	Larsen, C.P. et al. "CD40-gp39 Interactions Play a Critical Role During Allograft Rejection", <i>Transplantation</i> 61:4-9 (1996)
	Law, C-L. et al. "Analysis of Expression and Function of CD40 on Normal and Leukemic Human B Cell Precursors", <i>Leukemia</i> 4:732-738 (1990)
	Lederman, S. et al. "The Understanding of Contact-Dependent T-Cell Helper Function in Molecular, Cellular and Physiological Detail", <i>Res. Immunol.</i> 145:215-222 (1994)
	Mohan, C. et al. "Interaction Between CD40 and its Ligand gp39 in the Development of Murine Lupus Nephritis", <i>J. Immunol.</i> 154:1470-1480 (1995)
	Merck Manual of Diagnosis and Therapy, 16th Ed. "Idiopathic Infiltrative Diseases of the Lungs", Merck Research Laboratories, Rahway, NJ, pp. 718-720 (1992)
	O'Grady, J.T. et al. "CD40 Expression in Hodgkin's Disease", <i>Am. J. Path.</i> 144:2126 (1994).
	Paulie, S. et al. "A p50 Surface Antigen Restricted to Human Urinary Bladder Carcinomas and B Lymphocytes", <i>Cancer Immunol. Immunother.</i> 20:23-28 (1985)
	Potocnik, A.J. et al. "Expression of Activation Antigens on T Cells in Rheumatoid Arthritis Patients", <i>Scand. J. Immunol.</i> 31:213-224 (1990)
	Rao et al. "Reversal of Chronic Rejection in Mouse Aortic Allografts by Combined Treatment with CTLA-1g and Anti-CD40L Monoclonal Antibody", <i>Human Immunol.</i> 55:15 (1997)
	Stüber, E. et al. "Blocking the CD-40L-CD-40 Interaction in vivo Specifically Prevents the Priming of T Helper 1 Cells Through the Inhibition of Interleukin 12 Secretion", <i>J. Exp. Med.</i> 183:693-698 (1996)
	Uckun, F.M. et al. "Temporal Association of CD40 Antigen Expression with Discrete Stages of Human B-Cell Ontogeny and the Efficacy of Anti-CD40 Immunotoxins Against Clonogenic B-Lineage Acute Lymphoblastic Leukemia as well as B-Lineage Non-Hodgkin's Lymphoma Cells", <i>Blood</i> 76:2449-2456 (1990)
	Urashima, M. et al. "CD40 Ligand Triggered Interleukin-6 Secretion in Multiple Myeloma", <i>Blood</i> 85:1903-1912 (1995)
	Valent, P. et al. "Further Characterization of Surface Membrane Structures Expressed on Human Basophils and Mast Cells", <i>Int. Arch. Allergy Appl. Immunol.</i> 91:198-203 (1990)
	Westendorf, J.J. et al. "Molecular and Biological Role of CD40 in Multiple Myeloma", <i>Curr. Top. Microbiol. Immunol.</i> 194:63-72 (1995)
	Westendorf, J.J. et al. "CD40 Expressions In Malignant Plasma Cells", <i>J. Immunol.</i> 152:117-128 (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
A015/CON2SERIAL NO.  
10/015,832INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Susan L. Kalled, et al.CONFIRMATION NO.  
1235FILING DATE  
December 12, 2001GROUP  
1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER  
INITIAL

Yellin, M.J. et al. "Human Fibroblasts and Endothelial Cells Express CD40 and are Activated by CD40L+ Cells," Poster session at 9th International Congress of Immunology meeting in San Francisco, California (Abstract available July 23, 1995)

Yellin, M.J. et al. "Ligation of CD40 on Fibroblasts Induces CD54 (ICAM-1) and CD106 (VCAM-1) Upregulation and IL-6 Production and Proliferation," *J. Leuk. Biol.* 58:209-216 (1995)

Yellin, M.J. et al. "Functional Interactions of T Cells with Endothelial Cells: The Role Of CD40L-CD40 Mediated Signals," *J. Exp. Med.* 182:1857-1864 (1995)

Yellin M.J. et al. "In situ Characterization of CD40L and CD40 Expression in Glomerulonephritis (GN)", ASBMB/ASIP/AAI Joint Meeting (Abstract available May 1, 1996)

Yellin M.J. et al. "Function of CD40 Molecules Expressed on Cultured Synovial Membrane Fibroblasts", *FASEB J.* 9:A774 - Abstract No. 4483 (1995)

Young, L.S. et al. "Identification of a Human Epithelial Cell Surface Protein Sharing a Epitope with the C3d/Epstein-Barr Virus Receptor Molecule of B Lymphocytes," *Intl. J. Cancer* 43:786-794 (1989)

Biogen, Inc. Press Release, October 21, 1999, "Biogen Says it Has Halted Several Trials of Anti-CD40 Ligand Monoclonal Antibody"

Biogen, Inc. Press Release, November 2, 1999, "Biogen Says It Has Stopped Ongoing Trials of Anti-CD40 Ligand Monoclonal Antibody"

Press Release from Biogen website ([www.prnewswire.com](http://www.prnewswire.com)), "Biogen Says it Has Halted Several Trials of Anti-CD40 Ligand Monoclonal Antibody", October 21, 1999

Press Release from Biogen website ([www.prnewswire.com](http://www.prnewswire.com)), "Biogen Says it Has Stopped Ongoing Trials of Anti-CD40 Ligand Monoclonal Antibody", November 2, 1999

Press Release from IDEC Pharmaceuticals, Inc. (April 20, 2000)

Press Release from IDEC Pharmaceuticals, Inc. (January 29, 2001)

Written Opinion dated October 12, 1998 in PCT/US98/23482 (WO 98/30240)

January 8, 1999 Reply to Written Opinion dated October 12, 1998 in PCT/US98/23482 (WO 98/30240)

Written Opinion dated October 12, 1998 in PCT/US98/00573 (WO 98/30241)

January 8, 1999 Reply to Written Opinion dated October 12, 1998 in PCT/US98/00573 (WO 98/30241)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.